Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Ray-Coquard

Showing results (351-360 of 509) with videos related to

Pageof 51
Sort By:
The Lancet. Oncology|July 30, 2017
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialEric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, et al.
Gynecologic Oncology|November 18, 2018
Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trialClémence Romeo, Florence Joly, Isabelle Ray-Coquard, et al.
Future Oncology (London, England)|June 13, 2019
Compliance to regional recommendations for molecular analyses and management of advanced lung cancer patientsAurélie Swalduz, Pierre-Jean Souquet, Maurice Pérol, et al.
BMC Cancer|November 26, 2014
The off-label use of targeted therapies in sarcomas: the OUTC'S programLauriane Eberst, Claire Cropet, Axel Le Cesne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2020
Small-Cell Carcinoma of the Ovary, Hypercalcemic Type-Genetics, New Treatment Targets, and Current Management GuidelinesMarc Tischkowitz, Sidong Huang, Susana Banerjee, et al.
Cancers|November 11, 2022
Structural and Socio-Spatial Determinants Influencing Care and Survival of Patients with a Pancreatic Adenocarcinoma: Results of the PANDAURA CohortGaël S Roth, Yohan Fayet, Sakina Benmameche-Medjahed, et al.
Molecular Oncology|November 12, 2022
Ribosome biogenesis-based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO groupNour-El-Houda Mourksi, Cécile Dalban, Amélie Colombe-Vermorel, et al.
Lancet (London, England)|May 5, 2009
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trialsJulia Bohlius, Kurt Schmidlin, Corinne Brillant, et al.
The Cochrane Database of Systematic Reviews|July 10, 2009
Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient dataJulia Bohlius, Kurt Schmidlin, Corinne Brillant, et al.
European Journal of Cancer (Oxford, England : 1990)|July 17, 2024
Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETOJean-Yves Blay, Nicolas Penel, Maud Toulmonde, et al.
Pageof 51

Showing results (351-360 of 509) with videos related to

Sort By:
Pageof 51
The Lancet. Oncology|July 30, 2017
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialEric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, et al.
Gynecologic Oncology|November 18, 2018
Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trialClémence Romeo, Florence Joly, Isabelle Ray-Coquard, et al.
Future Oncology (London, England)|June 13, 2019
Compliance to regional recommendations for molecular analyses and management of advanced lung cancer patientsAurélie Swalduz, Pierre-Jean Souquet, Maurice Pérol, et al.
BMC Cancer|November 26, 2014
The off-label use of targeted therapies in sarcomas: the OUTC'S programLauriane Eberst, Claire Cropet, Axel Le Cesne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 12, 2020
Small-Cell Carcinoma of the Ovary, Hypercalcemic Type-Genetics, New Treatment Targets, and Current Management GuidelinesMarc Tischkowitz, Sidong Huang, Susana Banerjee, et al.
Cancers|November 11, 2022
Structural and Socio-Spatial Determinants Influencing Care and Survival of Patients with a Pancreatic Adenocarcinoma: Results of the PANDAURA CohortGaël S Roth, Yohan Fayet, Sakina Benmameche-Medjahed, et al.
Molecular Oncology|November 12, 2022
Ribosome biogenesis-based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO groupNour-El-Houda Mourksi, Cécile Dalban, Amélie Colombe-Vermorel, et al.
Lancet (London, England)|May 5, 2009
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trialsJulia Bohlius, Kurt Schmidlin, Corinne Brillant, et al.
The Cochrane Database of Systematic Reviews|July 10, 2009
Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient dataJulia Bohlius, Kurt Schmidlin, Corinne Brillant, et al.
European Journal of Cancer (Oxford, England : 1990)|July 17, 2024
Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETOJean-Yves Blay, Nicolas Penel, Maud Toulmonde, et al.
Pageof 51